Hypoparathyroidism.com provides clarity for patients and caregivers dealing with this rare and complex endocrine disorder
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, has launched Hypoparathyroidism.com, an educational website for patients and caregivers dealing with this rare and complex disorder. Affecting an estimated 80,000 Americans, hypoparathyroidism is characterized by a number of physical and mental symptoms, including uncontrollable muscle spasms and cramps, tetany, seizures, fatigue, anxiety, and depression.
“The Hypoparathyroidism Association welcomes the launch of Hypoparathyroidism.com and believes it will be an important resource for our community of patients, as well as our caregivers,” said James Sanders, president, Hypoparathyroidism Association, Inc. “As a hypoparathyroidism patient, it is uplifting to see NPS’ recognition of our community needs and its dedication to providing accurate information about this rare disorder that is so often misunderstood.”
The website, Hypoparathyroidism.com, was developed in conjunction with experts in the field as a resource to connect patients with hypoparathyroidism, their families, and the healthcare professionals who treat them and provide information for those seeking knowledge about the endocrine condition. It offers first-hand patient experiences and numerous downloadable resources including guidance on how to talk to your doctor about the disorder and how to track calcium, vitamin D and phosphorus levels in foods. Using video and easy-to-understand text, the website provides an in-depth look at the causes and symptoms of the disorder. Hypoparathyroidism.com is also designed to meet the needs of healthcare professionals interested in knowing more about this rare disorder. It provides them with an overview of diagnosis and management, an animation explaining the mechanism of the disorder and links to peer-reviewed journal articles for in-depth exploration.
“Diagnosing the condition that they suffer from is often a critical component for those living with a rare disorder, especially for patients coping with symptoms that are uncommon and imply multiple organ systems,” said Francois Nader, MD, president and chief executive officer of NPS Pharmaceuticals. “As such, we are proud to launch Hypoparathyroidism.com, as our contribution to offering patients and healthcare providers a dedicated educational resource that focuses on the unique needs of the hypoparathyroidism community.”
Links to additional resources, including patient support organizations, such as the Hypoparathyroidism Association, are available on the website. Other resources include links to the websites of the Thyroid Cancer Survivors’ Association, American Thyroid Association, U.S. National Library of Medicine, Clinical Trial Registry, National Organization for Rare Disorders and online Hypoparathyroidism support groups.
Hypoparathyroidism is a rare endocrine disorder in which the body produces insufficient levels of parathyroid hormone, the principal regulator of calcium and phosphorus. When the body has too little parathyroid hormone, blood calcium levels drop and phosphorus levels increase, which can cause a number of physical and mental symptoms, including uncontrollable muscle spasms and cramps, tetany, seizures, fatigue, anxiety, and depression. There is currently no FDA-approved replacement therapy for hypoparathyroidism, which is currently managed with large doses of calcium supplementation and active vitamin D therapy to raise the calcium levels in the blood and reduce the severity of symptoms. Over time, calcium may build up in the body and result in serious health risks, including calcifications in the kidneys, heart or brain.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan products to patients with rare disorders and few, if any, therapeutic options. NPS is advancing two late-stage registration programs. A New Drug Application is undergoing FDA review for Gattex® (teduglutide) as a treatment for adult short bowel syndrome (SBS) and a Phase 3 registration study has been completed for Natpara™ (recombinant human parathyroid hormone (rhPTH [1-84]) in adult hypoparathyroidism. NPS' earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin, and Nycomed (acquired by Takeda Pharmaceutical Company Limited).
"NPS," "NPS Pharmaceuticals," "Gattex," and "Natpara" are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.
Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on the company's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated to the company's business include, but are not limited to, the risks associated with any failure by the company to successfully complete its preclinical and clinical studies within the projected time frames or not at all, the risk of not gaining marketing approvals for Gattex and Natpara, the risks associated with the company's strategy, as well as other risk factors described in the company's periodic filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Form 10-Qs. All information in this press release is as of the date of this release and NPS undertakes no duty to update this information.